Skip to content
Menu

LB Pharmaceuticals Inc LBRX

Full chart Compare
Set alert

Price alert · LBRX

All alert types
38.85 USD -1.19 (-2.97%)

Regular-session close

38.85 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

38.57 Day range 40.67
15.33 52-week range 49.48
YTD
+74.53%
1 year
+146.04%

5D -2.29 (-5.41%)

404244FriMonTueWedThu40.04
Market cap
1.26B
EPS (ttm)
-1.12
Shares out
32.36M
Forward P/E
-6.79
YTD return
+74.53%
1-year return
+146.04%
50-day average
39.61
200-day average
33.96
Enterprise value
897.21M
Volume
303.06K
Avg volume
371.95K
Open
39.23
Previous close
40.04
Day's range
38.57 – 40.67
52-week range
15.33 – 49.48
Analysts
Strong Buy
Price target
58.00 (+49.3%)
Earnings date
Mar 25, 2027

Key statistics

Price / book
3.00
Free cash flow
-98.01M
Total cash
403.76M
Total debt
5.16M
Return on equity
-38.80%
Short % of float
22.60%

Fundamental scorecard

4 of 25 checks passed on LBRX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LBRX Revenue — quarterly 0
LBRX Net income — quarterly -59.07M
LBRX EPS — quarterly -1.79

Earnings

LBRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 25, 2027Dec 30, 2026-1.80———
Nov 5, 2026Sep 30, 2026-1.62-1.79-0.17-10.49%
Aug 11, 2026Jun 30, 2026-0.80366-1.71-0.91-112.78%
May 12, 2026Mar 31, 2026-0.75-0.67+0.08+10.67%
Mar 26, 2026Dec 31, 2025-0.45-0.450.000.00%
Nov 6, 2025Sep 30, 2025-0.57-0.61-0.04-7.02%

Upgrades / downgrades

LBRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 9, 2026Canaccord Genuityinit—Buy
Oct 6, 2026Guggenheiminit—Buy
Oct 5, 2026Roth CapitaldownBuyNeutral
Oct 2, 2026Needhaminit—Buy
Aug 24, 2026HC Wainwright & Co.mainBuyBuy
Aug 12, 2026BMO CapitalmainOutperformOutperform

About LB Pharmaceuticals Inc

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
lbpharma.us

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on LBRX — it syncs with the Stock Master app.

Insider holders

LBRX insider holders
InsiderRelationLatest transactionDateShares held
DEEP TRACK BIOTECHNOLOGY MASTER FUND LTDBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securitySep 11, 20250
NUSSBAUM RANDirectorConversion of Exercise of derivative securitySep 11, 20250
PONTIFAX MANAGEMENT 4 G.P. 2015, LTD.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securitySep 11, 20250
VIDA VENTURES GP III, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securitySep 11, 20250

Institution ownership

LBRX institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp10.36%3,352,804130.26MSep 29, 2026
Blackrock Inc.7.25%2,346,78591.17MSep 29, 2026
RA Capital Management, L.P.6.82%2,208,60485.80MSep 29, 2026
Caligan Partners, LP4.66%1,509,62158.65MSep 29, 2026
JPMORGAN CHASE & CO4.46%1,444,21556.11MSep 29, 2026
Spruce Street Capital LP4.34%1,404,77954.58MSep 29, 2026

Fund ownership

LBRX fund ownership
Holder% heldSharesValueReported
JPMorgan Trust II-JPMorgan Small Cap Growth Fund2.14%692,90526.92MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.08%672,00026.11MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.80%581,67722.60MSep 29, 2026
BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio1.75%567,62722.05MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.86%278,88710.83MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.76%245,4369.54MAug 30, 2026